71.51
price up icon0.53%   0.38
after-market Handel nachbörslich: 50.33 -21.18 -29.62%
loading
Schlusskurs vom Vortag:
$71.13
Offen:
$70.56
24-Stunden-Volumen:
3.69M
Relative Volume:
1.80
Marktkapitalisierung:
$13.21B
Einnahmen:
$2.53B
Nettoeinkommen (Verlust:
$-240.23M
KGV:
-45.10
EPS:
-1.5857
Netto-Cashflow:
$-20.46M
1W Leistung:
+2.69%
1M Leistung:
+4.61%
6M Leistung:
+15.21%
1J Leistung:
+6.70%
1-Tages-Spanne:
Value
$70.23
$72.83
1-Wochen-Bereich:
Value
$67.57
$72.83
52-Wochen-Spanne:
Value
$40.62
$79.62

Exact Sciences Corp Stock (EXAS) Company Profile

Name
Firmenname
Exact Sciences Corp
Name
Telefon
608-284-5700
Name
Adresse
5505 ENDEAVOR LANE, MADISON, WI
Name
Mitarbeiter
6,600
Name
Twitter
@exactsciences
Name
Nächster Verdiensttermin
2024-11-05
Name
Neueste SEC-Einreichungen
Name
EXAS's Discussions on Twitter

Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-08-28 Eingeleitet Wells Fargo Overweight
2024-06-27 Eingeleitet Scotiabank Sector Outperform
2024-06-03 Fortgesetzt Jefferies Buy
2024-01-02 Hochstufung The Benchmark Company Hold → Buy
2023-12-14 Eingeleitet Guggenheim Buy
2023-12-13 Eingeleitet Wolfe Research Outperform
2023-10-10 Hochstufung Piper Sandler Neutral → Overweight
2023-09-28 Eingeleitet Bernstein Outperform
2023-08-02 Herabstufung The Benchmark Company Buy → Hold
2023-05-10 Hochstufung Craig Hallum Hold → Buy
2023-05-05 Eingeleitet UBS Neutral
2023-03-09 Hochstufung Citigroup Neutral → Buy
2023-02-10 Herabstufung Credit Suisse Outperform → Neutral
2023-01-18 Herabstufung Raymond James Outperform → Mkt Perform
2022-10-19 Herabstufung Craig Hallum Buy → Hold
2022-08-25 Eingeleitet Credit Suisse Outperform
2022-06-03 Eingeleitet Piper Sandler Neutral
2021-11-03 Herabstufung Raymond James Strong Buy → Outperform
2021-07-29 Bestätigt BTIG Research Buy
2021-07-29 Bestätigt Canaccord Genuity Buy
2021-07-29 Bestätigt Oppenheimer Outperform
2021-07-29 Bestätigt Stifel Buy
2021-06-15 Eingeleitet Raymond James Strong Buy
2021-06-03 Eingeleitet Goldman Buy
2021-05-25 Eingeleitet Wells Fargo Equal Weight
2021-01-28 Eingeleitet Truist Buy
2020-10-29 Herabstufung UBS Buy → Neutral
2020-10-28 Herabstufung Citigroup Buy → Neutral
2020-10-08 Fortgesetzt BTIG Research Buy
2020-04-02 Eingeleitet Evercore ISI Outperform
2020-01-10 Fortgesetzt BTIG Research Buy
2020-01-07 Eingeleitet Citigroup Buy
2019-12-13 Eingeleitet Dougherty & Company Buy
2019-11-15 Eingeleitet Stifel Buy
2019-10-17 Bestätigt BofA/Merrill Buy
2019-10-01 Fortgesetzt Craig Hallum Buy
2019-09-26 Eingeleitet Oppenheimer Outperform
2019-02-26 Hochstufung Goldman Neutral → Buy
2018-10-09 Eingeleitet UBS Buy
2018-09-05 Fortgesetzt The Benchmark Company Hold
2018-08-13 Bestätigt Canaccord Genuity Buy
2018-04-03 Hochstufung BTIG Research Neutral → Buy
2018-01-29 Eingeleitet Goldman Neutral
2018-01-08 Bestätigt The Benchmark Company Buy
2017-11-13 Herabstufung Robert W. Baird Outperform → Neutral
2017-11-01 Herabstufung BTIG Research Buy → Neutral
Alle ansehen

Exact Sciences Corp Aktie (EXAS) Neueste Nachrichten

pulisher
05:28 AM

Exact Sciences: Q3 Earnings Snapshot - San Antonio Express-News

05:28 AM
pulisher
05:07 AM

After-hours movers: Super Micro Computer, Exact Sciences, Trump Media & Technology - Investing.com

05:07 AM
pulisher
05:04 AM

Exact Sciences Stock Plummets After Worse-Than-Expected Q3 Results, FY24 Guidance Below Estimates - Benzinga

05:04 AM
pulisher
04:41 AM

Exact Sciences Corp Q3 2024 Earnings: Revenue at $709M, EPS at -$0.21, Misses Estimates - GuruFocus.com

04:41 AM
pulisher
04:18 AM

Exact Sciences shares plummet on weak results, lowered guidance By Investing.com - Investing.com UK

04:18 AM
pulisher
04:05 AM

Exact Sciences Announces Third-Quarter 2024 Results - StockTitan

04:05 AM
pulisher
04:09 AM

New York State Common Retirement Fund Has $20.19 Million Stock Holdings in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat

04:09 AM
pulisher
Nov 04, 2024

3 Large-Cap Stocks to Buy Ahead of Likely Earnings Beat Tuesday - Yahoo Finance

Nov 04, 2024
pulisher
Nov 04, 2024

Exact Sciences Corp (EXAS) Stock Price Up 2.99% on Nov 4 - GuruFocus.com

Nov 04, 2024
pulisher
Nov 04, 2024

Exact Sciences to Participate in November Investor Conference - Marketscreener.com

Nov 04, 2024
pulisher
Oct 29, 2024

Canaccord Genuity sees upside potential for Exact Sciences shares, lifts PT - Investing.com

Oct 29, 2024
pulisher
Oct 29, 2024

Exact Sciences (EXAS) Moves to Strong Buy: Rationale Behind the Upgrade - Yahoo Finance

Oct 29, 2024
pulisher
Oct 29, 2024

Exact Sciences (EXAS) Set to Announce Quarterly Earnings on Tuesday - MarketBeat

Oct 29, 2024
pulisher
Oct 27, 2024

Exact Sciences Presents Multiple Studies at ACG 2024 Demonstrating Leadership in Noninvasive Colorectal Cancer Screening and Patient Engagement - Business Wire

Oct 27, 2024
pulisher
Oct 27, 2024

8,360 Shares in Exact Sciences Co. (NASDAQ:EXAS) Purchased by Sequoia Financial Advisors LLC - MarketBeat

Oct 27, 2024
pulisher
Oct 25, 2024

Exact Sciences Co. (NASDAQ:EXAS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Oct 25, 2024
pulisher
Oct 22, 2024

Will Screening Sales Drive Exact Sciences' Q3 Earnings? - Yahoo Finance

Oct 22, 2024
pulisher
Oct 21, 2024

Exact Sciences Corp (EXAS) Shares Gap Down to $69.69 on Oct 21 - GuruFocus.com

Oct 21, 2024
pulisher
Oct 19, 2024

Can This Beaten-Down Cathie Wood Stock Bounce Back? - MSN

Oct 19, 2024
pulisher
Oct 19, 2024

Friedenthal Financial Purchases New Stake in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat

Oct 19, 2024
pulisher
Oct 17, 2024

Exact Sciences Cor (EXAS-Q) QuotePress Release - The Globe and Mail

Oct 17, 2024
pulisher
Oct 16, 2024

Exact Sciences Corporation (EXAS) Bounced Back in Q3 - Yahoo Finance

Oct 16, 2024
pulisher
Oct 10, 2024

EXAS Gains FDA Nod for Cologuard Plus, Progresses With CRC Screening - Yahoo Finance

Oct 10, 2024
pulisher
Oct 10, 2024

Artemis Investment Management LLP Invests $7.27 Million in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat

Oct 10, 2024
pulisher
Oct 10, 2024

Exact Sciences EVP sells shares worth over $65k - Investing.com India

Oct 10, 2024
pulisher
Oct 09, 2024

Exact Sciences EVP sells shares worth over $65k By Investing.com - Investing.com Australia

Oct 09, 2024
pulisher
Oct 09, 2024

Exact Sciences Co. (NASDAQ:EXAS) EVP Brian Baranick Sells 929 Shares - MarketBeat

Oct 09, 2024
pulisher
Oct 09, 2024

Exact Sciences Corp (EXAS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance

Oct 09, 2024
pulisher
Oct 09, 2024

Exact Sciences Corp (EXAS) Q2 2024 Earnings Call Highlights: Str - GuruFocus.com

Oct 09, 2024
pulisher
Oct 09, 2024

Handelsbanken Fonder AB Acquires 9,400 Shares of Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat

Oct 09, 2024
pulisher
Oct 08, 2024

Exact Sciences Schedules Third Quarter 2024 Earnings Call - BioSpace

Oct 08, 2024
pulisher
Oct 07, 2024

Exact Sciences stock advances on Cologuard Plus approval, BTIG bullish By Investing.com - Investing.com Australia

Oct 07, 2024
pulisher
Oct 07, 2024

FMR LLC Bolsters Stake in Exact Sciences Corp - GuruFocus.com

Oct 07, 2024
pulisher
Oct 07, 2024

Exact Sciences stock advances on Cologuard Plus approval, BTIG bullish - Investing.com India

Oct 07, 2024
pulisher
Oct 07, 2024

FDA greenlights Exact Science’s newest home colorectal cancer test - Medical Device Network

Oct 07, 2024
pulisher
Oct 07, 2024

Exact Sciences wins FDA approval for Cologuard Plus colorectal cancer test - Yahoo Finance

Oct 07, 2024
pulisher
Oct 05, 2024

Exact Sciences Corporation (EXAS): A Buzzing AI Health Stock to Add to Your Portfolio - Insider Monkey

Oct 05, 2024
pulisher
Oct 05, 2024

10 Buzzing AI Health Stocks - Insider Monkey

Oct 05, 2024
pulisher
Oct 04, 2024

FDA approves Exact Sciences' advanced CRC screening test By Investing.com - Investing.com South Africa

Oct 04, 2024
pulisher
Oct 04, 2024

FDA approves Exact Sciences' advanced CRC screening test - Investing.com India

Oct 04, 2024
pulisher
Oct 04, 2024

Exact Sciences shares hold as FDA approves new Cologuard test - Investing.com

Oct 04, 2024
pulisher
Oct 04, 2024

FDA greenlights Exact Sciences’ Cologuard Plus - BioWorld Online

Oct 04, 2024
pulisher
Oct 04, 2024

Exact Sciences shares hold as FDA approves new Cologuard test By Investing.com - Investing.com Canada

Oct 04, 2024
pulisher
Oct 04, 2024

FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test - Yahoo Finance

Oct 04, 2024
pulisher
Oct 04, 2024

Is EXAS Stock a Smart Addition to Your Portfolio Right Now? - Yahoo Finance

Oct 04, 2024
pulisher
Oct 04, 2024

Exact Sciences (EXAS) Announces FDA Approval of Cologuard Plus Test - StreetInsider.com

Oct 04, 2024
pulisher
Oct 04, 2024

FDA Approves Exact Sciences’ Cologuard Plus Test, Setting a New Benchmark in Non-Invasive Colorectal Cancer Screening - The Bakersfield Californian

Oct 04, 2024
pulisher
Oct 04, 2024

Curbstone Financial Management Corp Decreases Holdings in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat

Oct 04, 2024

Finanzdaten der Exact Sciences Corp-Aktie (EXAS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$226.42
price up icon 3.48%
diagnostics_research LH
$229.11
price up icon 0.85%
diagnostics_research WAT
$387.17
price down icon 0.04%
$154.96
price up icon 0.96%
diagnostics_research MTD
$1,385.79
price up icon 1.60%
$415.98
price up icon 0.35%
Kapitalisierung:     |  Volumen (24h):